ProCE Banner Activity

Primary Analysis of Phase III HAVEN 2: Emicizumab Prophylaxis in Pediatric Hemophilia A With Factor VIII Inhibitors

Slideset Download
Conference Coverage
In an intraindividual comparison, emicizumab prophylaxis was associated with a greatly reduced risk of treated bleeds compared with prior treatment with bypassing agents.

Released: December 07, 2018

Expiration: December 06, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology